Dr. Dunbar is interested in atherogenic dyslipidemia and its treatment, and has particular expertise in the mechanism of action and adverse effects of nicotinic acid (niacin). He has developed sophisticated objective techniques to quantify the physical stigmata of flushing from niacin. He combines these techniques with laboratory pharmacodynamic studies to elucidate the integrated physiology of the response to niacin.
Dr. Dunbar specializes in the treatment of cholesterol disorders, and practices in the Preventive Cardiology Clinic at the Pereleman Center for Advanced Medicine
Khera AV, Qamar A, Reilly MP, Dunbar RL, Rader DJ: Effects of Niacin, Statin, and Fenofibrate on Circulating PCSK9 Levels
in Patients with Dyslipidemia. American Journal of Cardiology [Accepted] January 2015.
Dunbar RL, Nicholls SJ, Maki KC, Roth EM, Orloff DG, Curciof D, Johnson J, Kling D; Davidson MH: Effects of Omega-3 Carboxylic Acids on Lipoprotein Particles and Other Cardiovascular Risk Markers in High-Risk Statin-treated Patients with Residual Hypertriglyceridemia: a Randomized Controlled Double-Blind Trial. [Pending] 2015.
Millar JS, Reyes-Soffer G, Jumes P, Dunbar RL, deGoma EM, Rafeek H, Baer AL, Pollan L, Tohyama J, Liu Y, Johnson-Levonas AO, Wagner JA, Donovan DS, Karmally W, Ramakrishnan R, Holleran S, Obunike J, Lassman ME, Gutstein DE, Ginsberg HN, Rader DJ: CETP Inhibition with Anacetrapib Lowers LDL by Increasing ApoB Clearance. Journal of Clinical Investigation [Pending] 2015.
Tuteja S, Duffy D, Dunbar RL, Movva R, Gadi R, Bloedon LT, Cuchel M
: Pharmacokinetic Interactions of the Microsomal Triglyceride Transfer Protein Inhibitor, Lomitapide, with Drugs Commonly Used in the Management of Hypercholesterolemia. Pharmacotherapy 34(3): 213–314, March 2014.
Donovan J, Dunbar R, Biernat L, Logan D, Curtis M, Mancini M, Jirousek M: Phase 1 Single and Multiple Ascending Dose Study of CAT-2003, a Novel Activator of Lipoprotein Lipase, Demonstrates Reductions in Postprandial Triglycerides [Poster Presentation] JACC March 2014 Notes: 63rd Annual Scientific Session of the American College of Cardiology, Washington, DC, March 2014.
Maki KC, Orloff DG, Nicholls SJ, Dunbar RL, Roth EM, Curcio D, Johnson J, Kling D, Davidson MH: A Highly Bioavailable Omega-3 Free Fatty Acid Formulation Improves the Cardiovascular Risk Profile in High-Risk, Statin-Treated Patients With Residual Hypertriglyceridemia (the ESPRIT Trial). Clinical Therapeutics 35(9): 1400-1411, September 2013.
Dunbar RL, Cuchel M, Millar JS, Baer A, Poria R, Freifelder RH, Pryma DA, Billheimer JJ, Rader DJ: Niacin Does Not Accelerate Reverse Cholesterol Transport in Man [Poster Presentation] ATVB April 2013 Notes: Arteriosclerosis, Thrombosis and Vascular Biology 2013 Scientific Sessions, Lake Buena Vista, FL, April 2013.
Tuteja S, Dunbar R, Qu L, Li M, Mucksavage M, DerOhannessian S, Reilly M, Rader DJ: Perilipin 1 (PLIN1) genotype and not GPR109A associated with free fatty acid rebound following niacin administration [Poster Presentation] ATVB April 2013 Notes: Arteriosclerosis, Thrombosis and Vascular Biology 2013 Scientific Sessions, Lake Buena Vista, FL, April 2013.
deGoma,EM* and Dunbar, RL*, Jacoby, D, and French, B: Differences in absolute risk of cardiovascular events using risk-refinement tests: a systematic analysis of four cardiovascular risk equations. Atherosclerosis 227(1): 172-7, March 2013 Notes: *Co-first authors, equal contribution.
deGoma,EM, Davis, MD, Dunbar, RL, Mohler, ER, III, Greenland, P, and French, B: Discordance between non-HDL-cholesterol and LDL-particle measurements: Results from the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis March 2013.
back to top
Last updated: 10/31/2014
The Trustees of the University of Pennsylvania